Rhinocort Allergy

Proteinuria, Asthma, Itching + 16 more

Treatment

20 Active Studies for Rhinocort Allergy

Treatment for

Proteinuria

What is Rhinocort Allergy

Budesonide

The Generic name of this drug

Treatment Summary

Budesonide is a steroid medication used to treat inflammation of the lungs and intestines. It is prescribed for conditions such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was approved by the FDA in 1994 and is sold under the brand name Pulmicort.

Rhinocort

is the brand name

image of different drug pills on a surface

Rhinocort Allergy Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rhinocort

Budesonide

1994

134

Effectiveness

How Rhinocort Allergy Affects Patients

Budesonide is a medication used to treat respiratory and digestive issues caused by inflammation. The dose varies from person to person, but it is generally considered to be a safe drug. However, people should be aware of the potential side effects, like hypercorticism and suppression of the adrenal axis.

How Rhinocort Allergy works in the body

Corticosteroids work to reduce inflammation by decreasing the activity of certain proteins. These proteins can cause swelling or stop white blood cells from getting to the site of inflammation. Low doses of corticosteroids reduce inflammation, while higher doses can weaken the immune system. They also affect sodium and potassium levels in the body, leading to further changes in the body.

When to interrupt dosage

The endorsed dosage of Rhinocort Allergy relies upon the diagnosed condition, for instance Vasomotor Rhinitis, Crohn's Disease, and Chronic Obstructive Pulmonary Disease (COPD). The amount of dosage shifts, depending on the technique of delivery (e.g. Enema; Kit; Tablet - Rectal or Respiratory (inhalation)) as indicated in the table below.

Condition

Dosage

Administration

Proteinuria

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule - Oral, Capsule, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Tablet, extended release - Oral, Tablet, extended release, Capsule, coated pellets - Oral, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Enema; Kit; Tablet - Rectal, Enema; Kit; Tablet, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Capsule, delayed release - Oral, Tablet, orally disintegrating - Oral, Spray, metered - Nasal, Aerosol, metered - Nasal, Nasal, Capsule, delayed release, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, orally disintegrating, Patch - Cutaneous, Patch

Colitis, Collagenous

Nasal Polyps

Acute Coryza

Ulcerative Colitis

Nasal Congestion

Hypersensitivity

IGA Glomerulonephritis

Sinusitis

Crohn's Disease

Asthma

Crohn Disease

Itching

Skin Diseases

Chronic Obstructive Pulmonary Disease

Rhinitis, Vasomotor

Eosinophilic Esophagitis

Crohn Disease

maintenance therapy

Warnings

Rhinocort Allergy has five contraindications and should not be integrated with the ailments outlined in the following table.

Rhinocort Allergy Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Status Asthmaticus

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

There are 20 known major drug interactions with Rhinocort Allergy.

Common Rhinocort Allergy Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Budesonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abetimus.

Rhinocort Allergy Toxicity & Overdose Risk

Acute overdosing on corticosteroids is uncommon, but taking too much for too long can cause increased levels of cortisol and disrupt the hormone balance. If an overdose occurs, the dose of corticosteroids should be reduced temporarily. A 200mg dose is deadly for female mice, and 400mg for male mice.

image of a doctor in a lab doing drug, clinical research

Rhinocort Allergy Novel Uses: Which Conditions Have a Clinical Trial Featuring Rhinocort Allergy?

516 active clinical trials are currently examining the potential of Rhinocort Allergy to alleviate Chronic Obstructive Pulmonary Disease (COPD), Ulcerative Colitis and Allergic Symptoms.

Condition

Clinical Trials

Trial Phases

Asthma

81 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Chronic Obstructive Pulmonary Disease

70 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

IGA Glomerulonephritis

0 Actively Recruiting

Ulcerative Colitis

17 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4

Sinusitis

0 Actively Recruiting

Crohn's Disease

53 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Colitis, Collagenous

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

maintenance therapy

0 Actively Recruiting

Rhinitis, Vasomotor

1 Actively Recruiting

Not Applicable

Eosinophilic Esophagitis

0 Actively Recruiting

Acute Coryza

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Polyps

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Rhinocort Allergy Reviews: What are patients saying about Rhinocort Allergy?

Patient Review

6/18/2016

Rhinocort Allergy for Allergic Rhinitis Prevention

So far, so good! I've been using this for a few days now and it's given me the same relief as Nasonex at a lower price point.

Patient Review

11/11/2021

Rhinocort Allergy for Allergic Rhinitis Prevention

Budesonide unfortunately has caused my hair to fall out each of the three or four times I've tried it.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rhinocort allergy

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Rhinocort good for allergies?

"Budesonide is a steroid nasal spray that is a good first-choice option for nasal allergies. It is available as a lower-cost generic form. However, using it regularly for a long time can increase the risk for side effects, such as nosebleeds or fungal infection in the nose."

Answered by AI

Is Rhinocort Allergy discontinued?

"The brand rhinocort is no longer available but the generic prescription budesonide is available. There are no plans to discontinue generic prescription budesonide."

Answered by AI

When should you not use Rhinocort?

"Do not use Rhinocort if you are under 6 years of age or if it has expired as it may be harmful."

Answered by AI

Clinical Trials for Rhinocort Allergy

Have you considered Rhinocort Allergy clinical trials?

We made a collection of clinical trials featuring Rhinocort Allergy, we think they might fit your search criteria.

Have you considered Rhinocort Allergy clinical trials?

We made a collection of clinical trials featuring Rhinocort Allergy, we think they might fit your search criteria.

Image of Johns Hopkins University School of Medicine in Baltimore, United States.

N-Acetylglucosamine for Crohn's Disease

18 - 80

All Sexes

Baltimore, MD

Protein glycosylation is a critical post-translational modification that regulates protein trafficking and protein-protein interactions impacting a host of physiological processes. There is a growing appreciation of glycosylation defects in chronic human diseases, including Crohns disease. Crohns disease (CD), and the related condition of ulcerative colitis, are chronic inflammatory bowel diseases (IBD) that impact 3.1 million Americans. While the development of medications has revolutionized care of CD patients, clinical remission is only achieved in \~40% of patients a therapeutic ceiling that has not changed in 20 years. These data underscore the need for new CD treatment strategies. The investigators are focused on understanding the role of defective N-glycosylation in CD, as an innovative strategy to identify and develop new therapeutics. Depending on ancestral background, 7-25% of CD patients carry a pathogenic, missense mutation in the manganese (Mn) transporter ZIP8 (rs13107325; ZIP8 A391T). ZIP8 regulates systemic Mn homeostasis with ZIP8 391-Thr causing a relative Mn insufficiency. Mn is a required metal cofactor for enzymes regulating key cellular processes, like N-glycosylation. In the gut, protein N-glycosylation plays key roles in host-pathogen interactions, inflammation, and cell-cell interactions. The investigator's central hypothesis is that in patients carrying ZIP8 391-Thr - CD is exacerbated by aberrant N-glycosylation and that this defect can be targeted by specific, safe therapy. Supporting this hypothesis, Mn levels are reduced (\~15%) in ZIP8 391-Thr allele carriers and this is associated with a decrease in complex N-glycan branching in plasma. Further, the investigators uncovered a microbiota signature in the ileal mucosa that implicated altered bile acid homeostasis in ZIP8 391-Thr carriers. To better understand CD in ZIP8 391 carriers, the investigators generated a knock-in mouse model of ZIP8 391-Thr (Zip8393T/393T). Like patient data, the investigators observe reduced branching of N-glycans and disrupted bile acid homeostasis in the Zip8393T/393T mice. Promising human trials have shown that defects in N-glycan branching can be safely restored by raising levels of the rate-limiting metabolite UDP-N-acetylglucosamine (GlcNAc) via supplementation with free GlcNAc. The investigator's preliminary data in Zip8393T/393T mice have demonstrated that GlcNAc supplementation restores N-glycan branching deficits, rescues the defect in bile acid homeostasis, and ameliorates colitis susceptibility. Thus, the objective of the proposed research is to test a safe and effective therapy for patients carrying ZIP8 391-Thr and others who may have underlying changes in N-glycosylation. The investigators will perform a multi-center, randomized, double-blind, placebo-controlled cross-over study to test the safety and tolerability of oral GlcNAc as a proof-of-concept study. The investigators will use two cohorts stratified by ZIP8 391-Thr genotype status (carriers and non-carriers, n= 20 participants in each cohort, total= 40 participants).

Phase 2

Waitlist Available

Has No Placebo

Johns Hopkins University School of Medicine

Joanna Melia, MD

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions